EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

L26/O-310 The efficacy of hyaluronic acid enriched embryo transfer medium in women undergoing single blastocyst transfer: a multicentre randomised controlled trial

H. Cai, Z. Wang, Z. Huang, B. Huang, X. Xue, D. Xu, L. Jin, Y. Ni, Q. Wu, J. Shi

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.308 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von H. Cai und 9 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Does the use of hyaluronic acid (HA)-enriched embryo transfer medium improve live birth rates in women undergoing single fresh or vitrified-warmed blastocyst transfer? Summary answer The use of HA-enriched transfer medium did not significantly improve the live birth rates compared with standard medium in women undergoing single blastocyst transfer. What is known already Previous meta-analyses have suggested that HA supplementation in embryo transfer medium may enhance clinical pregnancy and live birth rates, leading to its widespread use in clinical practice. However, recent high-quality trials have reported conflicting results, and robust evidence from large, well-designed randomised controlled trials remains limited, specifically in the context of single blastocyst transfer. Study design, size, duration This was a multicentre, double-blind, randomised controlled trial conducted at four IVF centres across China. Between September 2024 and April 2025, 865 eligible women were randomly assigned in a 1:1 ratio to receive either EmbryoGlue® or a standard culture medium (control), using a central web-based randomisation system with computer-generated permuted blocks stratified by centre. Due to the distinct viscosity of EmbryoGlue®, embryologists were not blinded; however, participants and treating physicians remained blinded throughout the study. Participants/materials, setting, methods Women undergoing IVF/ICSI with a planned single blastocyst transfer (fresh or frozen–thawed) were included; those with uterine malformations, untreated hydrosalpinx, or prior trial participation were excluded. Blastocysts were incubated for 30 minutes in either high-HA (EmbryoGlue®) or low-HA (G-2 PLUS™) medium before transfer. The primary outcome was live birth rate. Secondary outcomes included biochemical and clinical pregnancy rates, miscarriage, ectopic pregnancy, and maternal and neonatal outcomes.All analyses followed the intention-to-treat principle. Main results and the role of chance A total of 865 women were randomised: 435 to EmbryoGlue® and 430 to G-2 PLUS™. Live birth occurred in 224/435 (51.5%) women in the high-HA group versus 205/430 (47.7%) in the low-HA group (risk ratio[RR] 1.08, 95% CI 0.95–1.23; P = 0.261). No statistically significant differences were observed for biochemical pregnancy (70.3% vs. 65.1%; RR 1.08, 95% CI 0.99–1.18; P = 0.100), clinical pregnancy (63.0% vs. 57.2%; RR 1.10, 95% CI 0.99–1.23; P = 0.083), or miscarriage (11.5% vs. 9.3%; RR 1.24, 95% CI 0.83–1.83; P = 0.291). One ectopic pregnancy occurred in the low-HA group. No major maternal or neonatal complications were observed among completed pregnancies. Subgroup analyses by transfer type (fresh vs. frozen), maternal age (<35 vs. ≥35 years), PGT-A status, blastocyst quality, and transfer rank (first vs. repeat), yielded consistent results. Limitations, reasons for caution The control medium contained low HA, which may have reduced the difference between groups and limited the study’s power to detect a true effect. Embryologists were not blinded due to the distinct viscosity of the HA-enriched medium; however, standardised protocols for embryo handling and transfer likely mitigated performance bias. Wider implications of the findings HA-enriched embryo transfer medium does not improve live birth or pregnancy outcomes in unselected women undergoing single blastocyst transfer. Further studies are needed to evaluate its efficacy in specific subgroups, such as those with recurrent implantation failure where biological plausibility for a benefit remains Trial registration number Yes

Zitieren

APA

Cai, H., Wang, Z., Huang, Z., Huang, B., Xue, X., Xu, D., Jin, L., Ni, Y., Wu, Q., & Shi, J. (2026). L26/O-310 The efficacy of hyaluronic acid enriched embryo transfer medium in women undergoing single blastocyst transfer: a multicentre randomised controlled trial. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.308

Vancouver

Cai H, Wang Z, Huang Z, Huang B, Xue X, Xu D, et al. L26/O-310 The efficacy of hyaluronic acid enriched embryo transfer medium in women undergoing single blastocyst transfer: a multicentre randomised controlled trial. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.308

BibTeX
@article{Cai2026,
  author = {Cai, H. and Wang, Z. and Huang, Z. and Huang, B. and Xue, X. and Xu, D. and Jin, L. and Ni, Y. and Wu, Q. and Shi, J.},
  title = {L26/O-310 The efficacy of hyaluronic acid enriched embryo transfer medium in women undergoing single blastocyst transfer: a multicentre randomised controlled trial},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.308}
}
Kostenlos starten →